Search

Displaying results 3671 - 3680 of 9886 in total
  1. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    As of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam. … Seletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam.

  2. Drug

    Potassium

    go.drugbank.com/drugs/DB14500
    ApprovedInvestigational

    It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. … Potassium is often a key ingredient for intravenous fluids, given to patients in clinical settings for rehydration, nutrition, and replenishment of electrolytes.

    Mixtures: Liquid Opti-minplex +d, Multi Mega Minerals With Vitamin DProducts: Port A Mins Super Potassium 99
  3. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).

  4. Drug

    Ketamine

    go.drugbank.com/drugs/DB01221
    ApprovedInvestigationalVet approved

    Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.

    Synonyms: DL-ketamine
  5. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    [L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. … [L33359] In December 2021, the FDA granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and [ritonavir], for the treatment of certain patients with

  6. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  7. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … [A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness.

  8. Drug

    Technetium Tc-99m tilmanocept

    go.drugbank.com/drugs/DB09266
    Approved

    Due to its relatively small molecular weight and small molecular diameter of 7 nm [A32168], technetium Tc-99m tilmanocept displays more rapid injection site clearance, high sentinel node extraction, and … It is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa dextran backbone [FDA Label].

  9. Drug

    Ocadusertib

    go.drugbank.com/drugs/DB21732
    Investigational

    Ocadusertib has a monoisotopic molecular weight of 459.19 Da. … Ocadusertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Ocadusertib is a serine/threonine kinase inhibitor.

  10. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    than BA in preclinical studies. … Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo.